HomeNewsBusinessMarketsA golden goose gone: Why Glenmark Pharma’s investors are unhappy with Nirma deal

A golden goose gone: Why Glenmark Pharma’s investors are unhappy with Nirma deal

Vaibhavi Ranjan • September 25, 2023 / 14:25 IST

Glenmark Pharma has hived off a 75 percent stake in Glenmark Life Sciences, which accounted for nearly 11 percent of its consolidated top line, and had a 20 percent EBITDA contribution, to clear debt

The stake sale, done at reasonable valuations, will help Glenmark Pharma turn debt-free.

To read the full story,

Are you a PRO subscriber? Sign In

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

Unlock exclusive discounts